Tumor volumetric analysis to correlate disease burden with response to dual immune checkpoint blockade in metastatic NSCLC

被引：0
|
作者：
Aminu, Muhammad
Vokes, Natalie I.
Saad, Maliazurina B.
Li, Hui
Hong, Lingzhi
Mohamed, S. Mohamed
Boom, John
Chen, Pingjun
Altan, Mehmet
Gandhi, Saumil
Swisher, Stephen
Antonoff, Mara B.
Pozadzides, Jenny V.
Blumenschein, George, Jr.
Gibbons, Don L.
Cascone, Tina
Elamin, Yasir Y.
Le, Xiuning
Negrao, Marcelo V.
Skoulidis, Ferdinandos
Tsao, Anne S.
Tu, Janet
Lee, J. Jack
Zhang, Jianjun
Heymach, John V.
Wu, Jia
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4393
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4393
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Bilateral murine tumor models for characterizing the response to immune checkpoint blockade
    Zemek, Rachael M.
    Fear, Vanessa S.
    Forbes, Cath
    de Jong, Emma
    Casey, Thomas H.
    Boon, Louis
    Lassmann, Timo
    Bosco, Anthony
    Millward, Michael J.
    Nowak, Anna K.
    Lake, Richard A.
    Lesterhuis, W. Joost
    NATURE PROTOCOLS, 2020, 15 (05) : 1628 - 1648
  • [32] Bilateral murine tumor models for characterizing the response to immune checkpoint blockade
    Rachael M. Zemek
    Vanessa S. Fear
    Cath Forbes
    Emma de Jong
    Thomas H. Casey
    Louis Boon
    Timo Lassmann
    Anthony Bosco
    Michael J. Millward
    Anna K. Nowak
    Richard A. Lake
    W. Joost Lesterhuis
    Nature Protocols, 2020, 15 : 1628 - 1648
  • [33] PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in NSCLC
    Liu, J.
    Zhou, H.
    Zhang, Y.
    Huang, Y.
    Yang, Y.
    Fang, W.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] Association of KMT2C/D Mutations with Tumor Mutation Burden and Response to Immune Checkpoint Inhibitors in NSCLC
    Liu, R.
    Niu, Y.
    Ma, T.
    Yuan, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S546 - S546
  • [35] Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer
    Chen, Ruifeng
    Hakimi, Kasim
    Zhang, Xinlian
    Messer, Karen
    Patel, Sandip Pravin
    ONCOLOGIST, 2022, 27 (09): : E739 - E745
  • [36] Response to Treatment for metastatic malignant Melanoma under double Immune Checkpoint Blockade
    Steimke, L.
    Rodig, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 15 - 15
  • [37] Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
    Schrock, A. B.
    Ouyang, C.
    Sandhu, J.
    Sokol, E.
    Jin, D.
    Ross, J. S.
    Miller, A.
    Lim, D.
    Amanam, I
    Chao, J.
    Catenacci, D.
    Cho, M.
    Braiteh, F.
    Klempner, S. J.
    Ali, S. M.
    Fakih, M.
    ANNALS OF ONCOLOGY, 2019, 30 (07) : 1096 - 1103
  • [38] Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade
    Akhand, Saeed S.
    Liu, Zian
    Purdy, Stephen C.
    Abdullah, Ammara
    Lin, Hang
    Cresswell, Gregory M.
    Ratliff, Timothy L.
    Wendt, Michael
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (12) : 1542 - 1553
  • [39] The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
    Moeckel, Camille
    Bakhl, Katrina
    Georgakopoulos-Soares, Ilias
    Zaravinos, Apostolos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [40] Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis
    Wan, Linghong
    Wang, Zhi
    Xue, Jinmin
    Yang, Huaju
    Zhu, Yuxi
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (09) : 5437 - 5449
12345